LumiraDx UK Ltd of London at MEDICA 2020 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

LumiraDx UK Ltd

3, More London Riverside, SE1 2AQ London
United Kingdom of Great Britain and Northern Ireland

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Media files

Our range of products

Product categories

  • 03  Diagnostic tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.02  Diagnostic rapid tests

Our products

Product category: Diagnostic rapid tests

LumiraDx Point of Care Diagnostic Platform

The LumiraDx Platform is an innovative, next generation point of care system that combines a small, portable instrument, advanced low cost test strip and seamless digital connectivity. Its proprietary technology enables it to deliver exceptional point of care clinical performance, while being simple and easy to use.

More Less

Product category: Diagnostic rapid tests

LumiraDx INR Test

The LumiraDx INR Test is an enzyme kinetic assay based on Thrombin activity.
The coagulation cascade is activated by the test reagents and INR is calculated from the measured PT-time. Haematocrit is also measured on the strip to ensure patients are within the 25-55% range.
The accuracy of the LumiraDx INR Test is comparable to the ACL Elite lab reference method.
Not available in the US

More Less

Product category: Diagnostic rapid tests

LumiraDx SARS CoV-2 Antigen Test

The LumiraDx SARS-CoV-2 Ag Test is a rapid microfluidic immunoassay detecting SARS-CoV-2 antigen.
The test uses nasal and nasopharyngeal swab samples to detect antigen nucleocapsid protein in under 12 minutes at point of care.
In clinical studies, the LumiraDx SARS-CoV-2 antigen test demonstrated 97.6% positive agreement versus RT-PCR in patients tested within 12 days of the onset of symptoms.

More Less

Product category: Diagnostic rapid tests

LumiraDx SARS-CoV-2 Antibody Test

The LumiraDx SARS-CoV-2 Ab Test is a microfluidic immunofluorescence assay for qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (capillary fingerstick or venous), plasma or serum for indication of recent or prior infection. Used with the LumiraDx Platform the Test delivers rapid results at the point of care.

More Less

Product category: Diagnostic rapid tests

LumiraDx D-Dimer Test

The LumiraDx D-Dimer Test is a rapid microfluidic immunoassay for quantitative determination of D-Dimer
The only D-Dimer Test providing fast, accurate, quantitative results in just 6 minutes from a fingerstick blood sample.1 
Supporting confident decisions at the point of care with the LumiraDx Platform.

1. Based on current information at the time of publishing

More Less

Company news

Date

Topic

Download

Nov 10, 2020

Global Partnership to Introduce a Connected, Point-of-Care Diagnostic Platform for COVID-19 Antigen Testing in Africa

London, UK – LumiraDx, the next generation point-of-care diagnostic company, announced today a $32 million global partnership with Africa Union, Africa Centres for Disease Control and Prevention (Africa CDC), Africa Medical Supplies Platform (AMSP), Bill and Melinda Gates Foundation (BMGF), and Clinton Health Access Initiative (CHAI) with the support of the COVID-19 Therapeutics Accelerator, The Mastercard Foundation and The Rockefeller Foundation to expand access to fast, accurate and equitable COVID-19 testing in Africa.

More Less

Aug 31, 2020

LumiraDx COVID-19 Antigen Test Achieves CE Mark

London, UK – LumiraDx, the next-generation point of care diagnostic company, announced today that, in addition to the Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration (FDA) on August 18, 2020, it had now also achieved CE Marking for its LumiraDx SARS-CoV-2 antigen test. The test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application in people with COVID-19 symptoms or who are at risk of the infection.  The test is the fastest, most sensitive COVID-19 antigen point of care test currently commercially available – and a crucial resource to European nations as they seek to improve access to rapid, accurate community testing.

The LumiraDx SARS-CoV-2 Ag Test is designed to be used in health care settings to provide an aid to rapid diagnosis of COVID-19. The test uses a nasal swab specimen from individuals at risk of, or with symptoms of, COVID-19 within the first 12 days of symptom onset. Clinical studies were performed at 6 sites across the US and UK with 257 subjects and demonstrated a 97.6% positive agreement and 96.6% negative agreement with RT-PCR.

More Less

About us

Company details

LumiraDx was founded in 2014 by a group of entrepreneurs: Ron Zwanziger, our Chairman and Chief Executive Officer; Dave Scott, Ph.D., our Chief Technology Officer; and Jerry McAleer, Ph.D., our Chief Scientist, who have a successful track record in building and scaling diagnostics businesses over three decades, including at companies such as Medisense, Inc., Inverness Medical Technology Inc. and Alere Inc. The company has raised approximately $600 million through debt and equity from institutional and strategic investors including the Bill & Melinda Gates Foundation, Morningside Ventures and U.S. Boston Capital Corporation. Based in the UK, with primary R&D and manufacturing operations in Stirling, Scotland, and supported by its worldwide affiliates to provide access in all major markets, LumiraDx has over 600 employees worldwide.

LumiraDx develops, manufactures and commercializes an innovative point-of-care diagnostic Platform. The LumiraDx Platform is designed to deliver lab comparable diagnostic results at the point of care in minutes. It is designed to be affordable and accessible for healthcare providers globally, and to strengthen community-based healthcare.

More Less